Ashvattha Therapeutics is advancing a new class of clinical-stage nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells only in regions of inflammation. Our targeted nanomedicine approach seeks to redefine precision medicine, empowering a new standard of care across ophthalmology, neurology, and inflammation. The Company has Phase 2 proof of concept data in wet AMD and DME patients demonstrating that monthly subcutaneous doses of migladendranib (nanomedicine) substantially (3-4-fold) reduces the need for intravitreal anti-VEGF injections, enabling an at-home administered product for patients. The Company has also demonstrated the ability to selectively target neuroinflammation (imaging) in multiple sclerosis patients with plans to advance a therapeutic nanomedicine to treat neuroinflammation in the next 12 months.